A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia¹

• المؤلفون الرئيسيون: Chutima Kunacheewa, Pakaporn Thongthang, Patompong Ungprasert, Eakkapol Utchariyaprasit, Weerapat Owattanapanich
• مؤلفون آخرون: Faculty of Medicine, Siriraj Hospital, Mahidol University
• التنسيق: مقال
• منشور في: 2020
• الموضوعات: Medicine
• الوصول للمادة أونلاين: https://repository.li.mahidol.ac.th/handle/123456789/52102
• المؤسسة: Mahidol University

© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Objectives: The addition of lenalidomide (LEN) to azacitidine (AZA) may further improve the outcomes of acute myeloid leukemia (AML) patients as well as patients with high-risk myelodysplastic syn...